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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD), the fourth leading 
cause of death worldwide, is a common evitable, manageable and progressive 
disease characterized by irreversible airflow restriction.1 Pharmacotherapy in 
COPD usually involves usage of numerous drugs, thereby increasing the risk 
of adverse drug events (ADEs) proportionally. In COPD, pharmacotherapy is 
given to reduce symptoms, reduce frequency and severity of exacerbations, 
improve health status and exercise tolerance. Bronchodilators are the mainstay 
in the pharmacological management of COPD. Short acting bronchodilators 
are given for immediate relief from symptoms, one or more long acting 
bronchodilators (long acting beta 2 agonist [LAβAs]) or long acting muscarinic 
antagonist [LAMAs] are used for long term maintenance treatment in subjects 
with moderate to severe disease.  
 Inhaled corticosteroids (ICS) are the central of treatment of Asthma but 
in the management of COPD their role is controversial.2-4 In COPD, the role of 
ICS is primarily to decrease the risk of exacerbations. The new GOLD strategy 
recommends the addition of second bronchodilator in patients with moderate 
airflow obstruction, reserving the ICS use in addition with a LABA and /or 
LAMA for patients with severe or very severe airflow obstruction and /or two 
or more exacerbations of COPD per year.5,6 But there is evidence that 
prescriptions are not always written according to GOLD recommendations or 
other national guidelines, resulting in a high proportion of patients being 
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treated with ICS unnecessarily and exposed to the risk of side effects in undue 
manner.7  
Adverse Drug Reaction (ADR) is defined by WHO, “As a response 
which is noxious and unintended and which occurs at doses normally used in 
humans for the prophylaxis, diagnosis or therapy of disease, or for the 
modification of physiological function”. Most of the drugs produce some 
adverse effects and carry the potential for causing injury, even if used properly.  
As widely used drugs act by interfering with one or more aspects of molecular 
and cellular function, all of them have the risk of producing some reaction 
which may not be desirable all the times. Hence the goal of pharmacotherapy 
cannot be to prescribe a risk free regimen but to ensure that the risks of drug 
therapy are kept as low as possible. Proper data about the adverse effects of 
drugs help physicians to prescribe drugs, balancing the benefits and hazards.8,9 
 Inappropriate drug usage may preclude ideal benefit due to increased 
medical cost, antimicrobial resistance, adverse effects and mortality. Therefore 
drug utilization studies have become a plausible means in evaluating the 
healthcare systems. COPD management usually involves more than one drug 
which may escalate the risk of ADEs. The present study was aimed at 
assessing the current drug practice and ADEs in COPD management in 
General Medicine OPD.10 Based on the total score, the drug-ADE association 
is termed definite, probable, possible or doubtful.  Irrational use of drug and 
inappropriate prescription is the two common phenomena in the developing 
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countries which cause a big problem for providing effective health care 
facilities.  
 Many studies have been conducted in the past on respiratory diseases, 
however to our knowledge published data particularly focused on COPD 
especially in India is limited. It was indeed necessary to assess the approach of 
Indian pulmonologists in treating COPD patients in order to refine the 
treatment practice. Drug utilization audits ensure safe and correct usage of 
drugs, which can either be quantitative or qualitative or a combination of both.  
More efforts should be made to improve the prescribing of medication 
indicated for COPD so that they align with current guidelines. Bronchodilators 
are the mainstay of current management and the search to improve existing 
bronchodilators will continue; so also will the search for novel anti-
inflammatory agents and therapeutic strategies to reverse the corticosteroid 
resistance seen in COPD. The present study aimed at assessing the current drug 
practice and ADEs in COPD management.11-14 
 Till date no study on pattern of drug use and their safety profile in the 
management of COPD has been conducted in this institution. Hence it was 
thought worthwhile to conduct a study to evaluate the pattern of drug use and 
their safety profile in the management of COPD in the General Medicine OPD 
of this institute. 
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REVIEW OF LITERATURE 
 Chronic obstructive pulmonary disease (COPD) is defined by the Global 
Initiative for Chronic obstructive lung disease (GOLD) as “a common 
preventable and treatable disease characterized by persistent air flow limitation 
that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and lung to noxious particles or 
gases.”15,16 The chronic airflow limitation typical of COPD is produced by a 
mixture of small airway disease (obstructive bronchiolitis) and parenchymal 
destruction (emphysema). Emphysema or the destruction of lung alveoli is a 
pathological term which is frequently used clinically and narrates only one of 
many structural abnormalities seen in patients with COPD.  
 Chronic bronchitis is defined as the presence of chronic cough and 
sputum production for at least 3 months of the year for at least 2 consecutive 
years in the absence of any other disease.16 Emphysema is defined as ‘‘a 
condition of the lung characterized by permanent, abnormal enlargement of the 
respiratory airspaces, accompanied by destruction of their walls without 
obvious gross fibrosis.17,18 
Theories related to aetiology of COPD 
 There are two hypotheses concerning the aetiology of COPD, the British 
and the Dutch hypothesis. According to the British hypothesis, presented at the 
CIBA guest symposium in 1959, the pathogenesis for chronic bronchitis was 
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based on host and exogenous factors, such as repeated chest infections, air 
pollution and smoking. According to this hypothesis it was suggested that the 
exogenous factors caused hypersecretion of mucus which inhibited the host 
defence, causing repeated acute or chronic respiratory tract infections and 
eventually to a decline in lung function. In contrast to the British theory, the 
Dutch hypothesis (DH) proposed that genetically determined host factors (such 
as genetic predisposition to atopy and bronchial hyperresponsiveness), 
combined with environmental factors (such as smoking) could predict the hosts 
response to the exogenous factors.19 
 According to this theory asthma, chronic bronchitis and emphysema are 
different expressions of a primary abnormality in the airways, and an 
interaction between genetic predispositions and exogenous factors determine 
which manifestation a subject develops. In the COPD field this postulated 
concept of genetically determined host factors provide an explanation as to 
why subjects exposed to identical exogenous factors (tobacco smoke and 
environmental pollution [TSEP]), developed different symptoms and 
manifestations i.e. chronic bronchitis on its own, or in addition to airflow 
obstruction. According to this hypothesis, asthma and COPD have a single 
genotype with two phenotypes.  
 The modern day view concerning the etiology of COPD began with 
Fletcher and his co-workers, and was later developed by others, and resembles 
the DH. Fletcher revealed that in susceptible smokers (comparable with the 
host factors), tobacco smoking is strongly related to chronic bronchitis and 
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airflow obstruction, and that these were two different diseases. One of the two 
diseases was chronic bronchitis (CB) without airflow obstruction and the other 
was airflow obstruction which in some individuals could co-exist with chronic 
bronchitis. For the first time Fletcher and his colleagues were able to show that 
tobacco smoking accelerated the decline of FEV1, and that smoking cessation 
could halt this rapid decline. It was demonstrated that different populations of 
smokers, i.e. susceptible and non-susceptible smokers, showed different trends 
in their lung function decline. Cigarette smoking is recognised as the cause of 
COPD in the vast majority of patients. Although not fully understood, it is 
widely accepted that an abnormal inflammatory response of the lungs to 
noxious particles and gases beyond the normal protective inflammatory 
response is involved in the development of COPD.20 
Epidemiology 
 In India, COPD is the second most common lung disorder after 
pulmonary tuberculosis. It is more commonly encountered in the middle-aged 
patients and is extremely rare below the age of 35 years. Prevalence of COPD 
in rural and urban areas is more or less equal.21 COPD has rapidly advanced 
globally as one of the most serious health issues. As per WHO estimates, 65 
million people have moderate to severe chronic obstructive pulmonary disease. 
More than 3 million people died of COPD in 2005, which corresponds to 5% of 
all deaths globally. It is a well known fact that almost 90% of COPD deaths 
occur in low- and middle-income countries (LMICs). 
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 At one point in time, COPD was more common in men, but because of 
increased tobacco use among women in high-income countries and the higher 
risk of exposure to indoor air pollution (such as biomass fuel used for cooking 
and heating) in low-income countries, COPD at present affects men and 
women almost equally. In 2002, COPD was the fifth leading cause of death. As 
per estimates, in 2020, COPD will attain the third position as the leading cause 
of death globally.2 
 COPD is more commonly seen in people living in polluted areas as well 
in those engaged in dusty occupations. Continued exposure to environmental 
and occupational dusts (EODs) is an important cause of chronic bronchial 
irritation which may also progress to airway obstruction after prolonged and 
persistent injury to the airways.22 COPD is one of the biggest causes of death in 
India today.  
 A varied range of prevalence of COPD in different states has been 
visualized in different studies. Men had a prevalence range of 2 to 22% and 
women between 1.2 to 19% in different population-based studies pan India. A 
graphical overview of India as per the disability adjusted life years (DALYs) 
rate due to COPD is shown in Figure 1.23 
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Figure 1: Geographic distribution of DALYs due to COPD per 100000 
population in India   
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Aetiology 
Tobacco smoking 
 The evidence that tobacco smoking is the most important aetiological 
factor in COPD is overwhelming. The greater the total tobacco exposure, 
higher the risk of developing COPD.24 Hukka and beedi smoking are equally 
harmful. Pipe and cigar smokers show greater mortality from COPD when 
compared with non-smokers. The cumulative amount of tobacco smoked is 
related to its adverse affects. 
 This is expressed as pack-years and is calculated by multiplying the 
number of packs (1 pack = 20 cigarettes) with years of smoking. Inhaled smoke 
in combination with latent host susceptibility and environmental factors 
produce COPD in 15% of smokers. Long-term cigarette smoking affects ciliary 
movement, causes hypertrophy and hyperplasia of mucus secreting glands.25 
Environmental exposures 
 Certain investigators have reported about increased respiratory 
symptoms in those living in urban surroundings in comparison to rural 
surroundings. Increased pollution in the urban settings might be the cause.  A 
concrete relationship between air pollution to chronic airflow obstruction is yet 
to be proven. Long-term exposure to smoke produced by biomass combustion, 
a common mode of cooking in some countries also seems to be a risk factor of 
significance for COPD amidst women in these countries. Ambient air pollution 
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has a much lesser importance as a risk factor for COPD when compared to 
cigarette smoking.26 
Occupation 
 COPD is frequently observed in persons who are engaged in 
occupations exposing them to either organic or inorganic dusts or to noxious 
gases.27 Occupations including coal mining, gold mining and cotton textile 
dust, have been suggested as risk factors for chronic airflow obstruction. 
Exposure to dust from coal mines was a prominent risk factor for emphysema 
in both smokers and non-smokers.28 
Socioeconomic status 
 Socioeconomic status (SES) is one of the most powerful determinants of 
health across a range of chronic diseases. SES is defined as an individual’s 
social and economic standing and serves as proxy for social or economic 
position or rank in a social group. More than a measure of income, SES 
encompasses several other measures including education, occupation, housing, 
assets, and participation in social organization. 
 While lower SES was found to be associated with greater COPD 
morbidity and mortality in HIC, few studies have examined the role of low SES 
in the prevalence of COPD among LMICs. An understanding of the role of 
SES and COPD in LMICs will potentially inform public interventions beyond 
harm reduction, i.e., tobacco cessation and decreased biomass fuel smoke 
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exposure, toward those aimed at disparities in SES. Factors limiting a 
comprehensive assessment of the relationship between SES and COPD in 
LMICs include the high cost of spirometry and limited data from which to 
analyze associations. Here, we describe the relationship between SES and 
COPD prevalence among the ten low- and middle-income settings in 
Argentina, Bangladesh, Chile, Peru, and Uruguay, which encompass a diversity 
of geographies, ethnicity, and variations in altitude and degree of 
urbanization.29 
Respiratory infections 
 Infections are often the precipitating cause of acute exacerbations of 
COPD (AECOPD) and contribute significantly to morbidity and mortality. 
Viral respiratory infections in infancy may cause airways obstruction in later 
life. 
Familial and Genetic Host Factor (FGF) 
 Alpha-1-antitrypsin (α1-AT) is a protease inhibitor (Pi), acts as an acute 
phase reactant and a potent inhibitor of serine proteases. The commonest allele 
in all populations is PiM and the most common phenotype PiMM.18 The 
common M allele is associated with normal α1-AT levels. The S allele is 
associated with slightly reduced α1-AT levels, and the Z allele, associated with 
markedly reduced α1-AT levels. Severe alpha-1-antitrypsin (α1-AT) deficiency 
is a proven genetic risk factor for COPD; there is increasing evidence that other 
genetic determinants also exist.  
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 Although only approximately 1% to 2% of COPD patients are found to 
have severe α1-AT deficiency as a contributing cause of COPD, these patients 
demonstrate that genetic factors can have a profound influence on the 
susceptibility for developing COPD. Cigarette smokers with severe α1-AT 
deficiency are more likely to develop COPD at early ages.30 
 Familial aggregation of chronic bronchitis has been well demonstrated. 
Incidence of α1-AT deficiency in patients presenting with COPD is 1% to 2% 
but increases to about 50% in patients with severe disease who are under 40 
years of age. 
Inflammation in COPD 
 As chronic inflammation is an important process in COPD, pro-
inflammatory mediators such as chemokines and cytokines will play an 
important role in the pathogenesis of COPD. There is now increasing 
recognition of COPD as a multi-component disease with manifested systemic 
complications.31 The disease is not restricted to just the airways, as emphysema 
and airflow limitation, but can also often present with significant 
extrapulmonary abnormalities. The identification of these cytokines in the 
plasma of patients with COPD strongly suggests that the local inflammatory 
response communicates with the systemic circulation via these mediators. 
 The local inflammatory process in the lungs may spill over into the 
systemic circulation to produce systemic changes either by direct effects of 
released chemokines and cytokines, or indirectly by modification and 
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activation of peripheral inflammatory cells. The intensity of the inflammatory 
process correlates with the severity of COPD, and there is also evidence that 
patients with high values of inflammatory markers when stable had a more 
rapid decline of lung function over time.32 
Body Mass Index (BMI)  
 Data from the Copenhagen City Heart Study (CCHS) showed that the 
severity of COPD tended to be greater in patients with low BMI (with low BMI 
defined as a BMI less than 20 kg/m2). In subjects with mild airflow limitation 
(FEV1>70% of predicted value) 3.5% of males and 12.5% of females also had 
low BMI. Studies have also shown that loss of skeletal muscle may also occur 
in COPD patients with normal weight.33 Weight loss in patients with COPD 
was an independent risk factor shown to increase the risk of exacerbations and 
all-cause mortality, independent of the degree of airflow limitation.34-39 Weight 
gain on the other hand, seemed to have a protective effect in normal and 
underweight patients with severe COPD. 
Pathogenesis of COPD 
 Emphysema and chronic bronchitis often are clinically grouped together 
under the heading of chronic obstructive pulmonary disease (COPD) because 
of their propensity to coexist. The commonest form of COPD is the 
combination of chronic bronchitis and pulmonary emphysema. Chronic 
bronchitis, however, does not always lead to emphysema nor do all cases of 
emphysema have changes of chronic bronchitis. The association of the two 
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conditions is principally linked to the common etiologic factors-most 
importantly tobacco smoke and air pollutants. 
 The definition of emphysema is morphologic, whereas chronic 
bronchitis is defined on the basis of clinical features such as the presence of 
chronic and recurrent cough with excessive mucus secretion. The anatomic 
distribution is partially different; chronic bronchitis initially involves the large 
airways, whereas emphysema affects the acinus.40 
Emphysema 
 The WHO has defined pulmonary emphysema as combination of 
permanent dilatation of air spaces distal to the terminal bronchioles and the 
destruction of the walls of dilated air spaces. Emphysema is characterized by 
abnormal permanent enlargement of the air spaces distal to the terminal 
bronchioles, accompanied by destruction of their walls without significant 
fibrosis. 
Classification of pulmonary emphysema as per WHO definition based on the 
portion of the acinus involved: 
1. Centriacinar (centrilobular) emphysema 
2. Panacinar (panlobular) emphysema 
3. Paraseptal (distal acinar) emphysema 
4. Irregular (para-cicatricial) emphysema 
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5. Mixed (unclassified) emphysema.23 
1. Centriacinar (Centrilobular) emphysema 
 The distinctive feature of centriacinar (centrilobular) emphysema is the 
pattern of involvement of the lobules: The central or proximal parts of the 
acini, formed by respiratory bronchioles, are affected, while distal alveoli are 
spared. This type of emphysema is most commonly seen as a consequence of 
cigarette smoking in people who do not have congenital deficiency of α1-
antitrypsin. 
2. Panacinar (Panlobular) emphysema 
 In panacinar (panlobular) emphysema, the acini are uniformly enlarged, 
from the level of the respiratory bronchiole to the terminal blind alveoli. In 
contrast with centriacinar emphysema, panacinar emphysema tends to occur 
more commonly in the lower lung zones and is the type of emphysema that 
occurs in α1-antitrypsin deficiency. 
3. Distal Acinar (Paraseptal) emphysema 
 In distal acinar (paraseptal) emphysema, the proximal portion of the 
acinus is normal but the distal part is primarily involved. The emphysema is 
more striking adjacent to the pleura, along the lobular connective tissue septa, 
and at the margins. 
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4. Irregular emphysema 
 Irregular emphysema, so named because the acinus is irregularly 
involved, is almost invariably associated with scarring, such as that resulting 
from healed inflammatory diseases. 
5. Mixed (Unclassified) emphysema 
 The same lung may show more than one type of emphysema. It is 
usually due to more severe involvement resulting in loss of clear-cut distinction 
between one type of emphysema and the other.  
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Figure 2: Major patterns of emphysema 
 
A. Diagram of normal structure of the acinus, the fundamental unit of the lung. 
B. Centriacinar emphysema with dilation that initially affects the respiratory 
bronchioles. 
C. Panacinar emphysema with initial distention of all the peripheral structures 
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Figure 3: Pathogenesis of Emphysema 
 
 Loss of cellular homeostasis in emphysema pathogenesis. Exposure to 
inhaled toxins (such as cigarette smoke) leads to epithelial cell death, 
inflammation, and extracellular matrix proteolysis. 
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Chronic bronchitis  
 Chronic bronchitis (CB) is defined clinically as persistent cough with 
expectoration on most days for at least three months of the year for two or 
more consecutive years. It is more common in middle-aged males than females; 
about 20% of adult men and 5% of adult women on an average have chronic 
bronchitis, but only very few of them progress to serious disabling COPD.  
Etiopathogenesis 
 The two most important etiologic factors responsible for majority of 
cases of chronic bronchitis are cigarette smoking and atmospheric pollution. 
Other factors are occupation, infection, familial and genetic factors.  
Smoking 
 Heavy smoking is the most identified factor implicated to cause chronic 
bronchitis and emphysema. The propensity of heavy cigarette smokers to 
develop chronic bronchitis is 4 to 10 times higher. 
 Long term cigarette smoking appears to cause actions on the lungs in 
these ways: 
i. Impairment of ciliary movement. 
ii. Preventing the function of alveolar macrophages. 
iii. Hypertrophy and hyperplasia of mucus secreting glands. 
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iv. Obstruction of small airways. 
v. Vagal stimulation leading to bronchoconstriction. 
Atmospheric pollution 
 Industrialised urban areas have a higher incidence of chronic bronchitis 
as a result of atmospheric pollutants. Sulfur dioxide, nitrogen dioxide, 
particulate dust and toxic fumes are some of the atmospheric pollutants which 
increase the risk of developing chronic bronchitis. 
Occupation 
 Workers engaged in certain occupations such as in cotton mills 
(byssinosis), plastic factories etc. are exposed to various organic or inorganic 
dusts which contribute to disabling chronic bronchitis in such individuals. 
Sputum production is generally observed in patients with chronic bronchitis. In 
patients with byssinosis the sputum will be brownish- black color. 
Infection 
 Bacterial, viral and mycoplasmal infections do not initiate chronic 
bronchitis but usually occur secondary to bronchitis. Cigarette smoke, however, 
predisposes to infection responsible for acute exacerbation in chronic 
bronchitis. 
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Familial and genetic factors (FGF) 
 There appears to be a poorly-defined familial tendency and genetic 
predisposition to develop disabling chronic bronchitis. However, it is more 
likely that non-smoker family members who remain in the air-pollution of 
home are significantly exposed to smoke (passive smoking) and hence have 
increased blood levels of carbon monoxide.41,42 
Diagnosis  
 COPD must be considered in patients with dyspnoea, chronic cough or 
sputum production, and/or a history of exposure to risk factors for COPD. 
Diagnosis is made using spirometry. Post-bronchodilator FEV1/FVC<0.70 
substantiates that there is persistent airflow limitation and therefore of COPD 
in patients with appropriate symptoms and prominent exposures to noxious 
stimuli. Spirometry is the most reproducible and objective measurement of 
airflow limitation. It is a noninvasive and readily available test. 
 The weak specificity of peak expiratory flow measurement renders it 
unreliable to be used alone as the only diagnostic test in COPD in spite of its 
good sensitivity.43 
  
Review of literature  
 
22 
 
Figure 4: Spirometer and spirometry for COPD diagnosis 
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Table 1: Key indicators for considering a diagnosis of COPD17 
Indicators 
Dyspnoea that is Progressive over time 
Characteristically worse with exercise 
Persistent 
Chronic cough May be intermittent and may be 
unproductive 
Recurrent wheeze 
Chronic sputum production Any pattern of chronic sputum production 
may indicate COPD 
Recurrent lower respiratory 
tract infections 
 
History of risk factors Host factors (such as genetic factors, 
congenital/developmental abnormalities 
etc) 
Tobacco smoke (including popular local 
preparations) 
Smoke from home cooking and heating 
fuels 
Occupational dusts, vapours, fumes, gases 
and other chemicals  
Family history of COPD 
and/or childhood factors 
For example low birth weight, childhood 
respiratory infections 
Differential diagnosis44 
 A major differential diagnosis is bronchial asthma. In some patients with 
chronic bronchial asthma, a clear distinction from COPD is not possible using 
Review of literature  
 
24 
 
current imaging and physiological testing techniques. Current management is 
similar to that of bronchial asthma. 
Table 2: Differential diagnosis of COPD 
Diagnosis Suggestive features 
COPD 
 
 
Onset in mid-life 
Symptoms slowly progressive 
History of tobacco smoking or exposure to 
other types of smoke 
Bronchial asthma 
  
Onset early in life (often childhood) 
Symptoms vary widely from day to day 
Symptoms worse at night/early morning 
Allergy, rhinitis and/or eczema also present 
Family history of asthma 
Obesity coexistence 
Congestive heart failure Chest x-ray shows dilated heart, pulmonary 
edema 
Pulmonary function tests indicate volume 
restriction, not airflow limitation 
Bronchiectasis  Large volumes of purulent sputum 
Three layered sputum 
Commonly associated with bacterial infection 
Chest x-ray/CT shows bronchial dilation, 
bronchial wall thickening 
Tuberculosis Onset all ages 
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Chest x-ray shows lung infiltrate 
Microbiological confirmation 
High local prevalence of tuberculosis 
Obliterative bronchiolitis Onset at younger age, non-smokers 
May have history of rheumatoid arthritis or 
acute fume exposure 
Seen after lung or bone marrow transplantation 
CT on expiration shows hypodense areas 
Diffuse panbronchiolitis Predominantly seen in patients of Asian 
descent 
Most patients are male and non-smokers 
Almost all have chronic sinusitis 
Chest x-ray and HRCT show diffuse small 
centrilobular nodular opacities and 
hyperinflation 
Alpha-1 Antitrypsin deficiency (AATD) screening17 
 The World Health Organization recommends that all patients with a 
diagnosis of COPD should be screened once especially in areas with high 
AATD prevalence. 
Assessment45 
 The goals of COPD assessment are to determine the severity of airflow 
limitation, its impact on the patient’s health status and the risk of future events 
in order to eventually guide therapy. 
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COPD assessment must consider the following aspects of the disease separately 
in order to achieve this: 
 The presence and severity of the spirometric abnormality 
 Current nature and magnitude of the patient’s symptoms 
 Exacerbation history and future risk 
 Presence of comorbidities 
Classification of severity of airflow obstruction 
 Specific spirometric cut-points are used for purposes of simplicity. 
Spirometry should be performed after the administration of an adequate dose of 
at least one short-acting inhaled bronchodilator in order to minimize variability. 
Table 3: Classification of airflow limitation severity in COPD based on 
post bronchodilator FEV1 (In patients with FEV1/FVC <0.70) 
 
Review of literature  
 
27 
 
 There is only a weak correlation between FEV1, symptoms and 
impairment of a patient’s health status. 
Assessment of symptoms 
 In the past, COPD was viewed as a disease largely characterized by 
breathlessness. However, it is now recognized that COPD affects patients 
beyond just dyspnoea. 
Revised combined COPD assessment 
 The “ABCD” assessment tool of the 2011 GOLD update was a major 
advancement from the simple spirometric grading system of the earlier versions 
of GOLD because it incorporated patient-reported outcomes and highlighted 
the importance of exacerbation prevention in the management of COPD. 
Management of COPD46  
An effective COPD management plan includes four components: 
1. Assess and Monitor Disease 
2. Reduce Risk Factors 
3. Manage Stable COPD 
4. Manage Exacerbations. 
 Management of Mild to Moderate COPD (Stages I and II) involves 
preventing disease progression by avoiding risk factors and using 
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pharmacotherapy when needed to control symptoms. Severe (Stage III) and 
Very Severe (Stage IV) COPD often requires integrating multiple disciplines, a 
number of treatment approaches, and the clinician’s undying commitment to 
support the patient as the disease progresses. 
 COPD patients may require specific counselling about smoking 
cessation, instruction in physical exercise, nutritional advice and continued 
nursing support. 
Goals of COPD management 
 Relieve symptoms 
 Prevent disease progression 
 Improve exercise tolerance 
 Improve health status 
 Prevent and treat complications 
 Prevent and treat exacerbations 
 Reduce mortality 
Non-pharmacological management of COPD 
 Optimum management of COPD requires non-pharmacological 
interventions combined with pharmacological treatment.  
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Non-pharmacological management options for COPD include 
i. Smoking cessation 
ii. Pulmonary rehabilitation 
iii. Pneumococcus and influenza vaccinations 
iv. Non-invasive positive pressure ventilation (NPPV) 
v. Long-term oxygen therapy (LTOT) 
vi. Surgery and bronchoscopic lung volume reduction 
Smoking cessation 
 Smoking cessation remains the only proven intervention to slow the 
decline of lung function and should be prioritized in the management of COPD 
patients. As smoking is the most important modifiable risk factor for COPD, 
quitting smoking is critical to reduce the occurrence and progression of the 
disease.47 All patients with COPD should be strongly urged to quit smoking and 
educated about the benefits of quitting. 
Pulmonary rehabilitation 
 In COPD, pulmonary rehabilitation has been demonstrated to improve 
health-related quality of life, dyspnoea, and exercise capacity. It has also been 
shown to reduce rates of hospitalization over a 6-12 month period. 
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Pneumococcus and influenza vaccinations 
 Patients with COPD should receive the influenza vaccine annually. 
Polyvalent pneumococcal vaccine is also recommended.36 Pneumococcal 
vaccinations, PCV13 and PPSV23, are recommended for all elderly patients.17 
PPSV23 has been shown to reduce the incidence of community-acquired 
pneumonia in COPD patients < 65 years, with an FEV1 < 40% predicted. 
Non-Invasive Positive Pressure Ventilation (NPPV) 
 The aim of delivering NPPV via nasal or facial mask is to improve 
hypoventilation and provide rest to the respiratory muscles in COPD patients. 
NPPV improves the outcome in severe exacerbations of COPD complicated by 
hypercapnia and respiratory acidosis. Clear benefits are observed in patients 
with COPD and coexisting obstructive sleep apnoea or obesity 
hypoventilation.48 
Long-Term Oxygen Therapy (LTOT) 
 Supplemental O2 is commonly prescribed for patients with exertional 
hypoxemia or nocturnal hypoxemia. Supplemental O2 is the only 
pharmacologic therapy demonstrated to unequivocally decrease mortality rates 
in patients with COPD.36 
Surgery and Bronchoscopic Lung Volume Reduction (SBLVR) 
 Surgical options for COPD include LVRS, bullectomy and lung 
transplantation. 
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Lung Volume Reduction Surgery (LVRS) 
 LVRS involves the surgical reduction of lung volume, with multiple 
excisions improving elastic recoil and reducing hyperinflation. It is beneficial 
in selected COPD patients with upper-lobe emphysema. 
Bullectomy 
 Bullectomy involves removal of one or more large bullae that do not 
contribute to gas exchange, decompressing the adjacent lung parenchyma and 
improving ventilation.49 
Lung transplantation 
 COPD is currently the second leading indication for lung 
transplantation. 
 Current recommendations are that candidates for lung transplantation 
should have severe disability despite maximal medical therapy and be free of 
comorbid conditions such as liver, renal, or cardiac disease.36 
Pharmacological management of COPD 
 The aim of pharmacologic therapy for COPD is to reduce symptoms, 
reduce the frequency and severity of exacerbations, improve exercise tolerance 
and health status. Presently, there is no conclusive clinical trial evidence that 
any currently available medications for COPD modify the long-term decline in 
lung function. 
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Bronchodilators 
 Bronchodilators are medications that increase FEV1 and/or change other 
spirometric variables.44 
Three main classes of bronchodilator are in current clinical use: 
Beta2 Adrenergic agonists (sympathomimetics) 
Theophylline (a methylxanthine) 
Anticholinergic agents (muscarinic receptor antagonists)50 
Beta2 Adrenergic agonists (sympathomimetics) 
 The principal action of beta2-agonists is stimulation of beta2-adrenergic 
receptors, which increases cyclic AMP, relax airway smooth muscle and 
reduces bronchoconstriction. 
 There are short-acting (SABA) and long-acting (LABA) beta2-agonists. 
Short-acting inhaled beta2-agonists such as salbutamol, levosalbutamol, 
terbutaline, and fenoterol have a relatively rapid onset of bronchodilator 
effect, which usually wears off within 4–6 hours. 
 Formoterol and salmeterol are twice-daily LABAs that significantly 
improve FEV1 and lung volumes, dyspnoea, health status, exacerbation 
rate and number of hospitalizations. Salmeterol and formoterol are 
formulated for twice-daily dosing, have duration of effect of 12 hours or 
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more with no loss of effectiveness overnight or with regular use in COPD 
patients. 
 Indacaterol, a novel beta2-agonist is approved by both the EMA and the 
FDA for the treatment of COPD. Indacaterol is a once daily LABA that 
improves breathlessness, health status and exacerbation rate.  
 Oladaterol and vilanterol are additional once daily LABAs that improve 
lung function and symptoms. 
Once-daily inhaled beta2 agonists are useful in patients with COPD and may 
have additive effects with LAMAs.49 
Side effects of beta2 agonists 
• Muscle tremor (direct effect on skeletal muscle β2 receptors) 
• Tachycardia (direct effect on atrial beta2 receptors, reflex effect from 
increased peripheral vasodilation via β2 receptors) 
• Hypokalemia (direct β2 effect on skeletal muscle uptake of K+) 
• Restlessness 
• Hypoxemia (↑ V̇/Q̇ mismatch due to reversal of hypoxic pulmonary 
vasoconstriction) 
• Metabolic effects (↑ FFA, glucose, lactate, pyruvate, insulin) 
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Antimuscarinic drugs 
 Antimuscarinic drugs block the bronchoconstrictor effects of 
acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle. 
Short-acting antimuscarinics (SAMAs) are ipratropium and oxitropium. Long 
acting antimuscarinic antagonists (LAMAs) are tiotropium, aclidinium, 
glycopyrronium bromide and umeclidinium.44 Ipratropium is probably the most 
frequently used short-acting anticholinergic drug at present. 
 The bronchodilating effect of short-acting inhaled anticholinergics lasts 
longer than that of short-acting beta2 agonists. Tiotropium has been formulated 
for once-daily dosing, providing 24-hour bronchodilation, and has a selectivity 
for M1 and M3 receptors. Treatment with tiotropium has shown symptom 
improvement, decreased hyperinflation, reduced dyspnoea, and improved 
quality of life. Clinical trials have shown a greater effect on exacerbation rates 
for LAMA treatment (tiotropium) versus LABA treatment.44 
 In COPD, anticholinergic drugs may be as effective as or even superior 
to beta 2 agonists. Anticholinergic drugs reduce air trapping and improve 
exercise tolerance in patients with COPD. 
Short-Acting Antimuscarinics (SAMA) 
 Ipratropium bromide is available as a pMDI and nebulized preparation. 
It has relatively slow onset of bronchodilation and is usually maximal 30-60 
min after inhalation but may last for 6-8 h. Preferably given by MDI three or 
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four times daily on a regular basis, rather than intermittently for symptom 
relief. LAMAs, like tiotropium bromide has replaced ipratropium bromide to a 
large extent. 
Long-Acting Muscarinic Antagonists (LAMAs) 
 LAMAs have now been developed for the treatment of COPD. 
Tiotropium bromide is a long-acting anticholinergic drug that is suitable for 
once-daily dosing as a DPI or via a soft mist mini nebulizer device. 
Figure 5: Dry powder inhaler 
 
 It was more effective than ipratropium four times daily in several 
studies; it also significantly reduces exacerbations. Over a 4-year period, 
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tiotropium displayed no effect on disease progression, but there was a positive 
impact in the functioning of the lung and health status and diminishment in 
exacerbations and all-cause mortality. 
 Glycopyrronium bromide and umeclidinium bromide are also once-daily 
LAMAs with very similar clinical effects to tiotropium. Aclidinium bromide 
has to be given twice daily. LAMAs are now becoming the bronchodilators of 
choice for patients with COPD. 
Side effects of antimuscarinic agents 
 Inhaled anticholinergic drugs are generally well tolerated. LAMAs 
cause dryness of the mouth in 10%–15% of patients, but this usually disappears 
during continued therapy. Urinary retention is occasionally seen in elderly 
patients.48 
Methylxanthines 
 A methylxanthine is a competitive, nonselective phosphodiesterase 
inhibitor that increases the intracellular cAMP level and activation of protein 
kinase A, resulting in smooth muscle relaxation and bronchodilation.49 
Theophylline is the most commonly used methylxanthine. It is metabolized by 
cytochrome P450 mixed function oxidases. Combining theophylline with 
salmeterol brings about an increased improvement in FEV1 and breathlessness 
than salmeterol alone.44 
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 Theophylline is still used as a bronchodilator in COPD, but inhaled 
anticholinergics and beta2 agonists are preferred. Theophylline tends to be 
added to these inhaled bronchodilators in patients with more severe disease and 
has been shown to give additional clinical improvement when added to a 
LABA. 
Table 4: Side effects of theophylline45 
Side effect Proposed mechanism 
Nausea and vomiting PDE4 inhibition 
Headaches PDE4 inhibition 
Gastric discomfort PDE4 inhibition 
Diuresis A1 receptor antagonism 
Cardiac arrhythmias PDE3 inhibition, A1 receptor antagonism 
Epileptic seizures A1 receptor antagonism 
Combination bronchodilator therapy 
 Combining bronchodilators with different mechanisms and durations of 
action may increase the degree of bronchodilation with a lower risk of side-
effects compared to increasing the dose of a single bronchodilator. 
Combinations of SABAs and SAMAs are superior compared to either 
medication alone in improving FEV1 and symptoms. Treatment with 
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formoterol and tiotropium in separate inhalers has a bigger impact on FEV1 
than either component alone. COPD patients whose symptoms are not well-
controlled with a single long-acting bronchodilator, another type of long acting 
bronchodilator is additionally prescribed.50 
 COPD patients who are treated at a lower dose of a LABA/LAMA 
combination two times a day have shown improvement in symptoms and health 
status.51 SABA/SAMA combinations, such as salbutamol/ipratropium, are 
popular. LABA/LAMA dual combination inhalers indacaterol/glycopyrronium, 
vilanterol/umeclidinium bromide, olodaterol/tiotropium bromide are all used 
once daily, whereas formoterol/glycopyrronium bromide, formoterol/ 
aclidinium bromide are used twice daily. Beneficial effects on lung function are 
evidenced with these combination drugs in comparison with either LABA or 
LAMA alone.52-54 
Inhaled corticosteroids (ICS) 
 In patients with moderate to very severe COPD and exacerbations, an 
ICS combined with a LABA is more effective than either component alone in 
improving lung function, health status and reducing exacerbations. ICSs have 
no effect on the progression of COPD, even when given to patients with 
presymptomatic disease. ICSs have no effect on mortality. ICSs reduce the 
number of exacerbations in patients with severe COPD (FEV1 < 50% 
predicted) who have frequent exacerbations and are recommended in these 
patients. In the ISOLDE study, fluticasone treatment significantly reduced the 
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number of exacerbations and slowed the loss of quality of life in patients with 
advanced COPD (FEV1 <50% predicted). Regular treatment with inhaled 
corticosteroids should only be considered for symptomatic patients with 
advanced COPD suffering from repeated exacerbations.55 
Triple inhaled therapy 
 Triple therapy involves the addition of a LAMA to LABA/ICS 
combination therapy for the treatment of COPD. Studies which included 
patients suffering from severe or very severe COPD, who had greater than one 
exacerbation of COPD per year have shown lesser number of hospitalizations 
and COPD exacerbation with LABA/ICS/LAMA triple therapy. Improvement 
in symptoms, pulmonary function, and quality of life scores were noticed with 
triple therapy when compared with LABA/ICS combination therapy and with 
LAMA monotherapy. 
 A systematic review which compared triple therapy vs. LABA/ICS 
combination therapy or tiotropium alone reported improvement in pulmonary 
function and health-related quality of life for the group treated with triple 
therapy. The safety profile of triple therapy was similar to that of other 
treatment options available. 
Oral glucocorticoids 
 The multiple side effects of oral glucocorticoids like steroid myopathy 
that can cause muscle weakness, reduced functionality, and respiratory failure 
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in patients with very severe COPD. The management of acute exacerbations 
require oral glucocorticoids, but in chronic daily treatment in COPD the 
benefits do not outweigh the high rate of systemic complications.44 
Phosphodiesterase-4 (PDE4) inhibitors 
 Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor and acts 
by blocking this enzyme activity, increasing intracellular levels of cAMP, 
which results in reduction of cellular inflammatory activity. Roflumilast is 
indicated for the treatment of patients with severe or very severe COPD (FEV1 
< 50% of predicted) who continue to have COPD exacerbations, cough and 
sputum despite maximal inhaled therapy. The recommended dose is 500 μg/day 
orally once daily. 
Side effects of PDE4 
 Nausea  
 Reduced appetite  
 Weight loss 
 Abdominal pain  
 Diarrhoea  
 Sleep disturbance  
 Headache44 
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Antibiotics 
 The indication for prophylactic antibiotics in COPD should be 
determined on a case-by-case basis. Prophylactic antibiotics are a third-line 
therapy for the treatment of exacerbators. The available evidence lends support 
to the use of Azithromycin 250 mg daily or Azithromycin 500 mg three times a 
week or the use of Erythromycin 500 mg twice daily for 1 year in patients with 
severe or very severe COPD and in exacerbators despite usual pharmacological 
treatment. Long-term use is associated with an increased risk of adverse events 
and development of bacterial resistance. 
Table 5: Main drugs for the treatment of COPD55 
Drug 
 
Dose, μg (except where 
otherwise indicated) 
Duration of 
action, hours 
Short-acting beta2 agonist 
Fenoterol 
Albuterol (Salbutamol)  
MDI 100 and 200 
MDI 100, 120, 200 
4-6 
4 to 6, 12 
Long-acting beta2 agonist 
Formoterol 
Salmeterol 
Indacaterol 
Olodaterol 
DPI 12 
MDI 25 and DPI 50 
DPI 150 and 300 
SMI 2.5 
12 
12 
24 
24 
Short-acting anticholinergic 
Ipratropium (bromide)  MDI 20-40 6-8 
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Long-acting anticholinergic  
Glycopyrronium (bromide)  
Tiotropium  
Umeclidinium (bromide)  
DPI 50  
SMI 2.5  
DPI 62.5 
12 to 24 
24 
24 
Beta2 agonist plus short-acting anticholinergic 
Fenoterol/ipratropium  
Salbutamol/ipratropium 
MDI 50/20  
MDI 120/20  
 
6 to 8 
6 to 8 
Beta2 agonist plus long-acting anticholinergic 
Formoterol/aclidinium  
Formoterol/glycopyrronium  
Indacaterol/glycopyrronium  
Vilanterol/umeclidinium  
Olodaterol/tiotropium  
DPI 12/400  
MDI 9.6/14.4  
DPI 110/50  
DPI 25/62.5  
SMI 2.5/2.5  
12 
12 
12 to 24 
24 
24 
Long-acting beta2 agonist plus inhaled corticosteroid  
Formoterol/beclomethasone  
Formoterol/budesonide  
 
Formoterol/mometasone 
Salmeterol/fluticasone  
 
 
Vilanterol/fluticasone 
MDI and DPI 6/100  
DPI 6/200, 12/400, and 
12/200 MDI 6/200  
MDI 5/50, 5/100, and 5/200  
DPI 5/100, 50/250, and 
50/500  
MDI 25/50, 25/125, and 
25/250 
DPI 25/100 
12 
12 
 
12 
12 
 
 
24 
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Phosphodiesterase-4 inhibitor  
Roflumilast  Tablet, 500 mg  24 
Macrolide  
Azithromycin  
 
Tablet, 250 and 500 mg  24 
 
 
 
Mucolytic  
N-acetylcysteine  Powder, 200 and 600 mg; 
syrup, 30 mg/mL; and 
tablet, 600 mg  
8 to 12 
 
(MDI: metered dose inhaler; DPI: dry powder inhaler; and SMI: soft mist 
inhaler)  
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Figure 6: Mechanism of action of bronchodilators 
 
 Pharmacological modulation of airway smooth muscle cell and 
mechanism of action of bronchodilators. Activating or facilitating effects are 
shown by green arrows; inhibitory or antagonistic effects are shown by red 
arrows.55 
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Drug utilization study (DUS) 
 Studies on drug utilization are a potential tool to evaluate healthcare 
systems. Data and evidence that are obtained from the period of pre marketing 
and post marketing are used as a reference to prescribe drugs in clinical 
practice. The leaps and bounds improvement in the marketing of new drugs, 
contrast in drug prescribing pattern, delayed adverse effects and the price of 
drug have enhanced the significance of DUS.  
 The primary focus of DUS is to imply prescription of drug in an optimal 
dose for the proper indication with the precise information and at a cost which 
is affordable, thereby facilitating rational use of drugs in a population. DUS 
contribute to rational drug use by improving our knowledge and understanding 
of drug use, and provide early signals of irrational use of drugs thereby helping 
us to intervene in a timely fashion to improve drug therapy. 
Definition 
 “Drug utilization is defined as the marketing, distribution, prescription 
and use of drugs in a society with special emphasis on the resulting medical, 
social and economic consequences.” 
WHO prescribing indicators 
• The total number of drugs prescribed on an average per prescription - 
measure the extent of polypharmacy 
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• Percentage of medicines prescribed by generic name 
• Percentage of drugs prescribed from essential drug list 
• Percentage of prescription with an antibiotic prescribed 
• Percentage of prescriptions with injections - measure the overall level 
of injection use. Propensity to overuse injections is very common 
Complementary indicators 
• Average drug cost per visit 
• Percentage of medicine cost spent on injection 
Normal values 
• Average number of drug per visit 2-3 
• Percentage of visit with an injection prescribed 16-20% 
• Percentage of generic drugs prescribed - 100% 
• Percentage of drugs prescribed from Essential Drug List 80-100% 
• Percentage of visit with antibiotics prescribed should not exceed 40% 
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Factors influencing drug utilization55 
1. Population related factor: change in total population, change in 
population demographic, change in health status of a population 
2. System related factor: change and transition associated with health 
system reform and restructuring changes in policies and programmes 
3. Research and technology related: new treatment approach 
4. Pharmaceutical industry: development of new drug product, promotion 
of drugs to physician, drug sampling, direct to consumer advertising 
5. Practice and people related: change in prescribing and dispensing 
practice  
Uses of DUS 
i. Facilitate rational use of drug 
ii. Increase our understanding of how drugs are being used 
iii. Generate hypothesis that set the agenda for further investigation and 
thus avoid prolonged irrational use of drugs 
iv. Assess whether interventions intended to improve drug use have had 
the desired impact 
v. By comparing data from different localities may identify and promotion 
of best practice  
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Pharmacovigilance 
 Pharmacovigilance is an important post-marketing tool in ensuring the 
safety of pharmaceutical product. It involves evaluating information gathered 
from the health care providers, pharmaceutical company and patients in order 
to understand the risks and benefits of a particular drug.  
These activities 
• Identify new information about adverse effects of the drug 
• Prevent harm to the patient 
 Major role of pharmacovigilance is to identify and evaluate safety 
signals. Safety signal refers to concern about an excess of adverse events 
compared to that would be expected with a product use.  
Definition 
Pharmacovigilance52 
 “Pharmacovigilance is the pharmacological science relating to the 
detection, assessment, understanding and prevention of adverse effects 
particularly long term and short term side effects of medicines.”  
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Adverse Event (AE) 
 Any untoward medical occurrence that may present during treatment 
with a pharmaceutical product but which does not necessarily have a causal 
relationship with this treatment is called as AE.  
Adverse Drug Reaction (ADR)53 
 A response which is noxious and unintended, and which occurs at doses 
normally used in humans for the prophylaxis, diagnosis, or therapy of disease, 
or for the modification of physiological function. An adverse drug reaction, 
contrary to an adverse event, is characterized by the suspicion of a causal 
relationship between the drug and the occurrence, i.e. judged as being at least 
possibly related to treatment by the reporting or a reviewing health 
professional. Any response to a medicinal product which is noxious and 
unintended is ADR. 
Serious adverse event or serious adverse drug reaction 
 A serious adverse event or reaction is any untoward medical occurrence 
that at any dose results in death or is life threatening. Life threatening refers to 
an event in which patient was at risk of death at the onset of event like: 
• Inpatient hospitalization or prolongation of existing hospitalization 
• Persistent or significant disability 
• Congenital anomaly or birth defect 
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Objectives 
 The main objectives of National Pharmacovigilance Programme are as 
following 
• To foster the culture of Adverse Event  notification and reporting 
• To establish a viable and broad based ADR monitoring programmes in 
India 
• To create an ADR database for the Indian population 
• To create awareness of ADR monitoring among people 
• To ensure optimum safety of drug products in Indian market 
• To create infrastructure for ongoing regulatory review of Periodic Safety 
Updates Regulators (PSURs) 
• To promote rational and safe use of medicines.  
• To contribute the knowledge of value, detriment, efficiency and hazard 
of medicines.  
• To encourage edification and clinical training.  
• To endorse healthy communication to the community.  
• To increase public protection from the new products.  
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Clinical importance 
 New drug released into market lack long term safety data. Prescribed 
drugs response varies due to interactions with drug and food.  Awareness about 
pharmacovigilance and practice according to it has a large impact on health 
care quality. Information on clinical, pathological and epidemiological 
information related to adverse reaction help us to fully understand adverse 
effects of drugs and for identifying patients at risk. ADR have the potential to 
provide insight into structure-activity relationship, pharmacokinetic, 
pharmacodynamic and genetic factors affecting the action of drugs. This may 
provide lead for other novel indications of the drug. Knowledge acquired 
following stringent monitoring on adverse effect of drug can prevent 
unnecessary suffering by patients and decrease financial loss of the patient due 
to inappropriate use of drug. 
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AIMS AND OBJECTIVES 
Aim: To evaluate pattern of drug use and study the safety profile of drugs used 
in the management of COPD. 
Objectives:  
1. To determine the utilization of drugs in General Medicine OPD for the 
management of COPD using WHO Drug use indicators. 
2. To analyze the prescribing trends of drugs for management of COPD 
in General Medicine OPD. 
3. To assess safety profile. 
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METHODOLOGY 
Materials and methods 
Study design 
 This study was a prospective cross sectional observational study. 
Study setting 
 This study was conducted in the Outpatient Department, Department of 
General Medicine, Sree Mookambika Institute of Medical Sciences, 
Kulasekharam, Kanyakumari District, Tamil Nadu. 
Study Period 
This study was done during the period January 2017-January 2018. 
Inclusion criteria 
• Patients diagnosed with COPD and on treatment. 
• Age group of 40 to 70 years of both genders. 
• Subjects willing to give informed consent were included in the study. 
Exclusion criteria 
• Patients with acute exacerbation of COPD. 
Materials and Methods 
 
54 
 
• Patients taking medications for other co-morbid conditions like diabetes 
mellitus, hypertension, and hyperlipidemia. 
Institutional Human Ethics Committee Approval 
Ethical clearance was obtained from Institutional Human Ethics 
Committee (IHEC) Ref. No: SMIMS/IHEC No: 1/ Protocol no: 25/2016 
(Appendix I) 
Study procedure 
 The study was carried out after getting approval from Institutional 
Human Ethics Committee (IHEC). Patients who come to General Medicine 
OPD satisfying inclusion and exclusion criteria were enrolled in the study. 
They were explained about the study and written informed consent (Appendix 
II) was obtained from each patient or their attender before recruiting them into 
the study. Details from the prescriptions in the case file were recorded from 
(Appendix III). The demographic data of the patients, presenting complaints, 
details of drugs used and adverse effect of drugs were recorded. Details of 
drugs included dose, route and frequency of medication. 
Assessment of drug use indicators 
Following drugs use indicators were assessed according to WHO 
guidelines. 
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Prescribing Indicators 
a) Average number of drugs per patient 
 
          Total  number of different drugs prescribed 
                     Number of patients surveyed 
 
b) Percentage of drugs prescribed by generic name  
 
 
 
c) Percentage of patients with injection prescribed 
 
 
 
d) Percentage of patients with inhaler use 
 
 
 
 
e) Percentage of patients with oral prescribed 
 
 
 
Number of drugs prescribed by generic name 
       X100 
Total number of drug prescribed  
 
Number of patients with injection prescribed 
         X100 
Total number of drug prescribed   
Number of patients with inhaler use    
      X100 
Total number of patients    
 
Number of patients with oral prescribed     
      X100 
Total number of drug prescribed   
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f) Percentage of patients with nebulization 
 
 
 
g) Percentage of drugs prescribed from Essential drug list (EDL) 
 
 
 
The data collected was compared with WHO values given below, 
• Average number of drugs per patient 2-3. 
• Percentage of patients with an injection prescribed 16-20 %. 
• Percentage of drugs prescribed by generic name- 100%. 
• Percentage of drugs prescribed from EDL 80-100%. 
Essential Drugs from National List of essential medicine (2017) India.54 
Prescribing pattern of drugs was evaluated by  
• Average number of drugs and maximum number of drugs prescribed for 
each patient. 
• Percentage of patients on monotherapy or combination of drugs in 
COPD. 
Number of patients with nebulization 
            X100 
Total number of patients   
 
Number of drugs prescribed from EDL     
              X100 
Total number of drugs prescribed   
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• Utilization of various classes of drugs in COPD. 
• Order and frequency in the utilization of drugs in COPD. 
• Adverse effects related to treatment with drugs for COPD. 
 Safety profile was assessed using WHO causality assessment. 
Analysis of data 
 The data collected were entered into Microsoft Excel and subsequently 
analyzed. Descriptive statistics was used for data analysis. 
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OBSERVATIONS AND RESULTS 
 Prospective evaluation of prescriptions of 150 patients who attended 
General Medicine OPD in Sree Mookambika Institute of Medical Sciences 
between January 2017 and January 2018 was done and the data were analyzed. 
Baseline demographic data  
Table 6: Age distribution of patients 
Age (years) Number Percentage (%) 
40-50 years 28 18.67 
51-60 years 58 38.67 
61-70 years 64 42.66 
Total 150 100.00 
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Figure 7: Age wise distribution of patients 
 
  
 The study population ranged from age 40-70 years. Mean age was 58.28 
years. Age group 61-70 years had the maximum number of patients and totaled 
64. The group comprising 51-60 years had 58 patients from the study 
population. The least number of patients were seen in the age group 41-50 
years which accounted for 28 patients. 
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Gender Distribution  
Table 7: Gender wise distribution of patients 
Gender Number Percentage (%) 
Male 85 56.67 
Female 65 43.33 
Total 150 100.00 
 
The study population showed a higher male preponderance with 56.67% male 
patients and 43.33% female patients. 
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Figure 8: Gender wise distribution of patients 
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Table 8: Inhaler use wise distribution of patients 
 
Inhaler use wise 
distribution 
Number Percentage (%) 
Yes 118 78.67 
No 32 21.33 
Total 150 100.00 
 
Inhaler therapy was prescribed to 118 patients indicating that 78.67% of 
the study population was prescribed inhaler therapy. 
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Figure 9: Inhaler use wise distribution of patients 
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Table 9: Injection use wise distribution of patients 
 
Injection use wise 
distribution 
Number Percentage (%) 
Yes 115 76.67 
No 35 23.33 
Total 150 100.00 
 
Injections were administered to 115 patients, which accounted for 
76.67% of the study population. 
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Figure 10: Injection use wise distribution of patients 
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Table 10: Nebulization use wise distribution of patients 
 
Nebulization use 
wise distribution 
Number Percentage (%) 
Yes 146 97.33 
No 4 02.67 
Total 150 100.00 
 
 Nebulization was prescribed to 146 patients indicating that 97.33% of 
the study population received nebulization therapy and that it was widely 
preferred. 
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Figure 11: Nebulization use wise distribution of patients 
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Prescribing Indicators Data  
 
a) Average number of drugs per patient 
Total number of different drugs prescribed  =  650   = 4.33 
Number of patients surveyed            150 
 
b) Percentage of drugs prescribed by generic name 
Number of drugs prescribed by generic name    
               X100= 447/650= 68.76% 
           Total number of drug prescribed             
 
 
c) Percentage of patients with injection prescribed 
Number of patients with injection prescribed         
   X100= 115/650= 17.69 
 Total number of drug prescribed           
 
 
d) Percentage of patients with inhaler prescribed 
Number of patients with inhaler use           
X100  = 118/150= 78.67 
        Total number of patients             
 
 
e) Percentage of patients with oral prescribed 
Number of patients with oral prescribed           
X100 = 243/650= 37.38 
       Total number of drugs prescribed     
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f) Percentage of patients with nebulization   
Number of patients with nebulization used           
X100 =  146/150= 97.33 
        Total number of patients                    
 
 
g) Percentage of drugs prescribed from Essential drug list (EDL) 
 
Number of drugs prescribed from EDL  
X100     =  408/650 = 62.76 
 Total number of drugs prescribed     
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Table 11: Summary of prescribing indicators data 
 
Prescribing indicator assessed Average/Percentage  WHO standard 
Average number of drugs per 
patient  
4.33 2-3 
Percentage of drugs prescribed 
by generic name 
68.76% 100% 
Percentage of patients with 
injections  
17.69% 16-20% 
Percentage of drugs prescribed 
from EDL 
62.76% 80-100% 
 
Polypharmacy was observed in the prescriptions (4.33) compared to WHO 
value (2-3). 
Drugs were prescribed by generic name (68.76%) which is below the WHO 
value (100%). 
Injection use was 17.69% which meets the WHO criteria (16-20%). 
Prescription of drugs from EDL (62.76%) which is below the WHO criteria 
(80-100%). 
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Utilization of various classes of drugs in COPD 
Table 12: Frequency of distribution of drugs in each prescription 
Number of drugs in each prescription Number Percentage (%) 
Three drugs 20 13.33 
Four drugs 61 40.67 
Five drugs 24 16.00 
Six drugs  45 30 
Total 150 100.00 
 
Prescriptions with a combination of 4 drugs amounted to 61 prescriptions and 
accounted for 40.67% of the total prescriptions. 
Prescriptions with a combination of 6 drugs accounted for 30% of the total 
prescriptions. 
Prescriptions with a combination of 5 drugs accounted for 16% of the total 
prescriptions. 
Prescriptions with a combination of 3 drugs accounted for 13.33% of the total 
prescriptions. 
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Figure 12: Frequency of distribution of drugs in each prescription 
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Table 13: Most commonly used drug class in the study population 
Most commonly used drug Number Percentage (%) 
Beta-2 agonist 149 40.38 
Anti-cholinergic  0 00.00 
Deriphyllin (Hydroxyethyl 
theophylline)  
101 27.37 
Steroid  0 00.00 
Combination  119 32.25 
Total 369 100.00 
 
Beta-2 agonist was the most commonly used class of drug (n=149, 
40.38%). No anti-cholinergic or steroid monotherapy were given. Combination 
of drugs used (n=119, 32.25%). 
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Figure 13: Most commonly used drug class in the study population 
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Table 14: Most commonly used drug by oral route of administration 
 
Most commonly used drug by oral route  Number Percentage (%) 
Salbutamol 148 59.44 
Deriphyllin (Hydroxyethyl theophylline)  101 40.56 
Total 249 100.00 
 
 Commonest drug prescribed orally is Salbutamol n=148. Deriphyllin 
was prescribed to 40.56%. 
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Figure 14: Most commonly used drug by oral route of administration 
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Table 15:  Most commonly used drug by inhalation 
 
Most commonly used 
drug by inhalation  
Number Percentage (%) 
No inhalation  31 20.67 
Levosalbutamol 53 35.33 
Salbutamol+ipratropium 56 37.33 
Formoterol+Fluticasone 10 06.67 
Total 150 100.00 
 
The combination of Salbutamol and ipratropium was the most 
commonly prescribed drugs (n=56, 37.33%). The least prescribed was 
formoterol and fluticasone combination (n=10, 6.67%). 
 
 
 
 
Observations and Results 
 
78 
 
 
Table 16:  Most commonly used drug by injection 
 
Most commonly used drug by 
injection   
Number Percentage (%) 
No injection  34 22.67 
Dexamethasone+Deriphyllin 116 77.33 
Total 150 100.00 
 
Dexamethasone and deriphyllin combination was prescribed as injection 
to 116 patients. 
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Table 17:  Most commonly used drug by nebulization 
 
Most commonly used drug by 
nebulization  
Number Percentage (%) 
No nebulization 4 02.67 
Salbutamol+ ipratropium 146 97.33 
Total 150 100.00 
 
 Salbutamol and ipratropium nebulization was given to 146 patients. 
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Table 18: Frequency and percentage of patients with ADRs 
 
Type of ADR Number Percentage (%) 
Tremor 5 62.50 
Hoarseness of voice  1 12.50 
Bitter taste  1 12.50 
Hypersensitivity  1 12.50 
Total 8 100.00 
 
Total ADRs reported was 8. Tremor was the most common ADR 
observed in 5 patients. 
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Figure 15: Frequency and percentage of patients with ADRs 
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Table 19: Causality Assessment of ADRs according to WHO 
  
WHO Causality Assessment Scale  Number Percentage (%) 
Certain   
Probable/Likely    
Possible 7 87.5% 
Unlikely  1 12.5% 
Conditional/Unclassified    
Total 8 100.00 
 
The maximum ADRs observed were possible according to WHO 
causality assessment. 
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Figure 16: Causality Assessment of ADRs according to WHO 
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DISCUSSION 
The present study was undertaken to determine the drug utilization 
pattern and safety profile in the management of COPD in the General Medicine 
Outpatient Department in Sree Mookambika Institute of Medical Sciences, 
Kulasekharam, Kanyakumari district. The objective of the study was to 
determine the utilization of drugs with the reference of WHO drug use 
indicators, prescribing trends and assess safety profile.  
Treatment of COPD with multiple complications using minimal number 
of medications poses a challenge to the treating physician as treatment requires 
specific combination of drugs. Drug combinations can be prescribed for 
treatment as well as prophylaxis of COPD. In the treatment of COPD, it is 
essential to maintain a balance between the number of medications prescribed 
and achieving treatment goals with minimal adverse effects. 
 COPD with co-morbid conditions necessitated the use of various classes 
of drugs that include directly and indirectly acting bronchodilators, anti-
secretary agents, antihistamines and antimicrobial agents. The administration of 
these groups of drugs relieves bronchoconstriction, secretion and infection. 
Combination of drugs in COPD management plays a pivotal role in reducing 
morbidity and mortality. In the present study, all the above classes of drugs 
were prescribed for the treatment of patients diagnosed with COPD without 
other complications. 
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 COPD can affect any age group but it is most commonly seen affecting 
middle aged and elderly population. Morbidity and mortality in COPD can be 
reduced with early diagnosis and initiation of treatment. Pattern of drug utilized 
to treat COPD varies pan India. Drug availability, socioeconomic status of the 
patient, area of living and co-morbidity conditions can influence the 
prescription pattern of drugs in COPD. This present study was conducted to 
observe the drug utilization pattern and their safety in the south Indian 
population diagnosed with COPD. 
 The present study included 150 patients with COPD. Patients in the age 
group 40-70 years were included in the study. 42.66% was in the age group 61-
70 years. Only 28 people were aged between 40 to 50 years. Parbiaz AK55 and 
Lopez AD, et.al.56 study also showed that the prevalence of COPD was more in 
the age group 60-70 years with 53%. The impact of gender on expression of 
COPD has received even lesser attention in India. Tobacco smoking is an 
important factor for the development of COPD in males whereas indoor air 
pollution and biomass fuel may play a significant role in the development of 
COPD in women. Jain NK, et.al.57 studied 720 patients regarding etiological 
and risk factors leading to COPD with correlation to gender.  The study results 
concluded that COPD was more common in men compared to females. 
Silverman EK, et al.58 study had the same observations. Similar results were 
observed in the present study wherein males were afflicted more than females 
(56.67% males and 43.33% females) with COPD. 
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 The choice of inhaler device for patients with COPD depends upon 
multiple attributes. Efficient delivery of inhaled medication is essential for the 
success of COPD therapy. The inhaler device may contribute to optimal drug 
delivery and also impact patient adherence. A wide range of inhalers are 
available, including pressurized metered dose inhaler (pMDI), dry powder 
inhaler, nebulizers, and spinhaler. Advantages and disadvantages are present 
for each type of device. In this study, maximum number of patients used 
inhaler which contributes to 78.67%. Maithu M, et.al.59 studied use of inhalers 
in 245 COPD patients.  The study results expressed similar percentage use of 
inhalers. Newman SP study showed 76% of people used inhalers in the 
treatment of COPD. The present study results and the above study results 
indicate that inhalers are the most commonly preferred route for drug delivery 
in COPD management. 
 Rational treatment depends upon the selection of proper route for the 
administration of drugs based on the severity of COPD. Systemic route of 
administration has long been a standard for the treatment of COPD; however, 
the optimal strategy for dosing and administration is continually debated. 
Andrew Woods J, et.al.60 observed that systemic administration of drugs have 
significantly relieved the symptoms of COPD by improving airflow, decreasing 
treatment failure, reducing the risk of relapse, and curtailing the length of 
hospital stay. Further attacks of COPD can be prevented by therapy with oral or 
inhalational medication.  Recent data suggested that initiation of parenteral 
therapy has more efficacy in the traditional treatment guidelines of COPD. In 
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this study population, 115 members were administered injections.  Only 35 
were not given injections. This study results significantly correlated with other 
studies Lindenauer PK, et.al.61 
 Nebulization based therapy is the cornerstone of treatment for patients 
with COPD. Appropriate use of nebulization has significant impact compared 
to other modes of administration in the COPD management.  GOLD strategy 
document recommends nebulizers for specific patient populations (patients 
with very low inspiratory flow rate in whom nebulizer treatment may provide 
more benefits than inhalers. Further GOLD recommends evaluating the 
benefits of nebulizer treatment symptomatically and continuing treatment as 
long as similar benefits are not achievable by simpler, cheaper, and more 
potable alternatives. Dhand R, et.al.62 and Berlinski A63 studies showed 
beneficial effects of nebulization use in the treatment of COPD.  In both studies 
nebulization was the preferred mode of drug administration for COPD 
treatment with maximum number of patients receiving nebulization. In the 
present study, maximum patients received nebulization (n=146). 
 Drug utilization studies can provide insight into a pattern, quality, 
determinants and outcome of drug use. In this study, a total of 150 
prescriptions were observed for prescribing indicators.  4.33 was the average 
number of drugs per patient. Mahadeo PS, et.al.64 studied prescription pattern 
of drugs in 284 COPD patients. This study data concluded that average number 
of drugs per prescription were 7.  It is higher than the WHO norms. In a study 
done by Mazher M, et.al.65 results showed 5 drugs per prescription. In this 
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present study, the average number of drugs prescribed was 4.33.  This is 
slightly similar to the average of both the above mentioned studies.  This 
indicator is very important as it indicates the degree of polypharmacy and 
providing insight for review and educational intervention in regular practice.  
WHO has guidelines in place for combination of drugs for treatment of COPD. 
 Generic drugs are most commonly used in the treatment of COPD 
because of their cost-effectiveness.  According to WHO, there should be 100% 
usage of generic drugs in the treatment of COPD. In some conditions, it cannot 
be followed due to unavailability of generic drugs as mono or in combination 
therapy.  Kothai R, et.al.66 conducted a study on 150 COPD patients. They 
observed 36.66% of drugs were prescribed by generic name, which is lower 
compared to WHO guidelines. Tamas AGH, et.al.67 study showed 42.56% of 
drugs were prescribed by generic name. In the present study, 68.76% of the 
drugs were prescribed by generic name. These studies have not measured up to 
WHO guidelines. These observations may be due to unavailability of generic 
drugs. In COPD most of the drugs were used in combinations. These 
combinations may not be available as generic drugs and due to this lesser 
percentage was observed in the studies. In polypharmcy prescriptions, some 
drugs may be prescribed other than generic drugs for better patient safety and 
efficacy. 
 The burden of disease in terms of morbidity was obtained for each 
country from the Institute for Health Matrix and Evaluation (IHME) database. 
This is the most recent and reliable source of data on burden of disease which 
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has been frequently cited in global studies. COPD is one of the highest ranked 
disease in low income countries. To identify treatment of different stages of 
COPD two major guidelines were considered. Treatments were assigned either 
to gain and maintain disease control or to manage episodes. To maintain 
uniformity in the treatment, WHO prepared essential drug list for COPD. 
 A study by Yaser TB, et.al.68 on COPD patients showed nearly 90% of 
drugs were prescribed from essential drug list in the management of COPD. It 
was lesser in low income areas of India. The average percentage of drugs 
prescribed from essential drug list is 80-90% across India. In the present study, 
408 drugs were prescribed from essential drug list, which contributes to 
62.76% of essential drug use. Cameron A, et al.69 study observed 75.34% of 
drugs were prescribed from essential drug list. There is a variation in the 
studies regarding prescription of drugs as per essential drug list. 
 According to WHO guidelines 80-100 % drugs should be prescribed 
from the EDL.  The present study results showed less percentage of essential 
drugs in the prescriptions. This could be as a result of unavailability of essential 
drugs in the form of combination during the study period. 
 Currently, there are no specific classes of drugs available for COPD to 
reduce the progressive decline in lung function which is the hallmark of this 
disease.  The present pharmacological treatment of COPD is symptomatic and 
it is mainly based on various classes of drugs mainly bronchodilators, anti-
secretary agents, antihistamines, anti-inflammatory (glucocorticoids) and 
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antibiotics. Glucocorticoids are not generally recommended for patients with 
stable mild to moderate COPD due to their lack of efficacy, side effects. 
 A total of 650 drugs were prescribed in the present study for 150 
patients.  A combination of 3 to 6 drugs was used for better treatment outcome. 
Pauwels RA, et al.70 suggested a combination of various classes of 3 to 4 drugs 
have shown better treatment outcome than combination of two drugs of 
different class or three drugs in the same class. Rennard SI71 concluded in his 
study that a combination of different classes of drugs reduced the progression 
of COPD and relieved the symptoms compared to monotherapy. The current 
study observations showed 61 patients were prescribed 4 drugs per patient and 
45 patients were prescribed 6 drugs per patient.  20 and 24 patients were 
prescribed 3 and 5 drugs each respectively. 
 COPD guidelines provide advice about the appropriate use of various 
medications in treating patients with this condition. Combination of drug 
therapy is recommended by GOLD guidelines for the better management of 
COPD patients. The common classes of drugs used in pharmacological 
management of COPD are beta-2 agonist (salbutamol, salmeterol, formoterol), 
anticholinergic drugs (ipratropium and tiotropium), methylxanthines 
(deriphyllin), inhaled glucocorticoids (fluticasone, budesonide), oral 
glucocorticoids (prednisolone, methylprednisolone), parenteral glucocorticoids 
(dexamethasone) and phosphodiesterase 4 inhibitors (roflumilast) Michel R.72 
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 Bronchodilators play a major role in the treatment of COPD.  Indirectly 
acting bronchodilators will increase the effect of directly acting 
bronchodilators.  The bronchodilator effect can be enhanced with the co-
administration of deriphyllin. Inflammation is also one of the major symptoms 
in COPD which can be suppressed with the use of glucocorticoids.  The above 
classes of drug combination play a major role in the treatment of COPD. 
Donnell DE, et.al.73 study evaluated use of bronchodilators in 23 patients with 
COPD. He concluded that bronchodilators reduce mechanical restriction, 
increased ventilator capacity, decreased respiratory discomfort and increased 
the exercise capacity. All the patients showed significant result compared to 
placebo. Qaseem A, et.al.74 observed that there is an improvement in COPD 
symptoms of upto 60% with the usage of beta-2 agonist. In this present study, 
149 patients were given beta-2 agonists. 
 Methylxanthines are directly acting bronchodilators. These drugs are 
mainly combined and administered with beta-2 agonist.  In this class, 
deriphyllin was used with combination of salbutamol in the treatment of 
COPD. Mitsuko K, et.al.75 suggested combination of short acting beta-2 agonist 
with deriphyllin improves the patient condition effectively. Graham D, et.al.76 
study combined low dose of xanthines with other drugs in the treatment of 
COPD. This study includes 1424 patients, in that maximum number of patients 
showed better treatment outcome compared to other combinations. The present 
study also was similar to the above mentioned studies where 101 patients out of 
total 150 patients were given deriphyllin with the combination of  
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beta-2 agonists. 119 patients have been given a combination of different classes 
of drugs. 
 Long acting glucocorticoid (dexamethasone) with deriphyllin was 
administered as an injection to 116 patients.  This steroid suppresses the 
inflammation and deriphyllin increases the action of beta-2 agonist and dilate 
the bronchus.  Combination of anti-inflammatory with directly acting 
bronchodilator plays a major role in severe and acute COPD management. 
Mohammad EA, et.al.77 administered 34 COPD patients with dexamethasone. 
They were observed to increase the respiratory rate and decrease dyspnoea.  
Koc I et al78 administered dexamethasone to COPD patients for 3 months.  He 
observed it decreased the inflammation, cytokine formation and improvement 
in the symptoms of COPD. Dexamethasone was given in the form of injection 
in this study and similar effect was observed in comparison to the above 
studies. 
 In our study, the frequency of ADRs was 8. The most common ADR 
was tremors, 5. In this study, Salbutamol was the most commonly used drug. 
The known adverse effect of Salbutamol was tremors. In a study by Sestini P, 
et.al79., the causality assessment of ADR had been done using the WHO scale 
in which majority were possible (95.46%) with a less number of certain, 
probable reactions. Similarly in our study, more frequency was towards 
possible ADRs (87.5%). 
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 Limitations of our study were less sample size, socioeconomic status of 
the patients were not analyzed and defined daily dose was not calculated which 
could have provided more information on total cost of management of COPD. 
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CONCLUSION 
 The pattern of drugs used in COPD was studied in 150 patients of Sree 
Mookambika Institute of Medical Sciences from the period of January 2017 to 
January 2018. From our study findings, we were able to conclude that: 
1. Mean age of study population was 58.28 years. 
2. Male preponderance was higher compared to females. 
3. Average number of drugs per patient was 4.33, which was higher than 
WHO standards (2-3). 
4. 68.76% of drugs were prescribed with generic name which was lower 
than WHO standard (100%). 
5. Only 17.69% of drugs were prescribed by injection, which is similar to 
WHO standard (16-20%). 
6. 62.76% of drugs were from EDL which was lower than WHO 
standard (80-100%). 
7. 78.67% of patients used inhaler. 
8. 76.67% of patients were administered injections. 
9. 97.33% of patients used nebulization. 
10.  61 patients had prescriptions where 4 drugs were prescribed. 
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11. Most commonly used class of drugs were beta-2 agonist, 149. 
12. Among oral medications, salbutamol was most common, 148. 
13. Among combination therapy, salbutamol + ipratropium was most 
common, 56. 
14.  116 patients were prescribed dexamethasone + deriphyllin. 
15. Salbutamol + ipratropium were the maximum prescribed by 
nebulization, 146. 
16. Most common adverse effect was tremor, 5. 
17. Maximum ADR was possible (87.5%) as per WHO causality 
assessment scale. 
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CONSENT FORM 
 
Title of the project:  “Pattern of drug use and their safety profile in the management 
of COPD in a tertiary care hospital.”  
 
 
Participant’s name:                             Address: 
 
 
 
 
The details of the study have been provided to me in writing and explained to me in 
my own language. I confirm that I have understood the above study and had the 
opportunity to ask questions. I understand that my participation in the study is 
voluntary and that I am free to withdraw at any time, without giving any reason, 
without the medical care that will normally be provided by the hospital being affected. 
I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). I have been given an information sheet 
giving details of the study. I fully consent to participate in the above study.  
 
(I also consent / do not consent to use my stored biological samples for future 
scientific purposes: Yes/ No – if applicable) 
 
 
 
Signature of the participant: ______________________ Date: _____________ 
 
 
 
 
Signature of the witness: ________________________ Date: _____________ 
 
Name and address of the witness: 
 
Signature of the investigator: ________________________ Date: _____________ 
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